Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy symbols : Lly save search
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27 (Crawled : 00:00) - prnewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.49%
H: 0.84%
C: -0.07%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: -0.09%
H: 1.42%
C: 1.1%
ibi310 first cancer colon therapy study
Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | $20.07 -14.18% 1K
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: -0.0%
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 0.26%
H: 1.36%
C: 1.36%
AZNCF | $138.88 -4.19% 960
|
Health Technology
|
| O: -0.85%
H: 1.12%
C: 0.43%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
UCBJY | $63.874 -4.38% 11K
|
Manufacturing
|
| O: 1.46%
H: 0.44%
C: 0.44%
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: -0.27%
H: 0.0%
C: -1.17%
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.2%
H: 0.14%
C: -0.48%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -0.06%
H: 0.46%
C: 0.29%
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: -0.69%
H: 1.42%
C: 1.22%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 2.37%
H: 1.51%
C: 0.79%
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: -0.65%
H: 1.63%
C: 1.48%
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
|
| O: -0.88%
H: 1.46%
C: 1.13%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: 0.0%
AZN | $68.75 -0.26% -0.26% 7.6M
|
Health Technology
|
| O: -2.81%
H: 2.08%
C: 1.38%
AMGN | $265.505 -0.66% -0.67% 1.7M
|
Health Technology
|
| O: -0.35%
H: 1.15%
C: 0.96%
lung reach cancer cell diagnostics therapy market
Jaguar Gene Therapy Announces FDA Clearance of IND to Study JAG201 in a Genetic Form of Autism Spectrum Disorder and Phelan-McDermid Syndrome
Published: 2024-01-31 (Crawled : 15:00) - biospace.com/
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.84%
H: 2.02%
C: -0.73%
jag201 fda genetic clearance therapy study
CAR T-Cell Therapy Market to Register Stunning Growth During the Study Period (2019-2032) | DelveInsight
Published: 2024-01-23 (Crawled : 22:00) - prnewswire.com
ACLX | $56.94 -1.95% -1.98% 380K
|
|
| O: 1.59%
H: 1.14%
C: -1.42%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.61%
H: 1.52%
C: 0.03%
PSTX | $2.43 -10.99% -12.35% 600K
|
Health Technology
|
| O: 1.57%
H: 4.94%
C: 1.54%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 0.29%
H: 0.15%
C: -1.95%
BEAM | $25.64 -1.12% -1.13% 1.8M
|
Health Technology
|
| O: 1.88%
H: 0.88%
C: -2.79%
t-cell therapy growth study market
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
Published: 2024-01-23 (Crawled : 17:00) - prnewswire.com
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
genetic association positive research meeting trial therapy
Children's Hospital of Philadelphia Performs First in U.S. Gene Therapy Procedure to Treat Genetic Hearing Loss
Published: 2024-01-23 (Crawled : 17:00) - prnewswire.com
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
first genetic hospital treat therapy
AAV Vectors in Gene Therapy Market is Predicted to Observe Skyrocketed Growth During the Study Period (2019-2032) | DelveInsight `
Published: 2024-01-16 (Crawled : 22:00) - prnewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -1.83%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.77%
H: 0.17%
C: -1.65%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.45%
H: 0.06%
C: -0.5%
RGNX | $18.04 -0.28% -0.28% 350K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -7.15%
ADVM | $11.55 -1.54% -1.56% 99K
|
Health Technology
|
| O: -0.69%
H: 2.32%
C: -0.12%
therapy growth study market
Gene Therapy Global Market is Projected to Grow at a CAGR of ~19% by 2028, Predicts DelveInsight
Published: 2024-01-12 (Crawled : 22:00) - prnewswire.com
TGTX | $14.08 -0.57% -0.57% 2.3M
|
Health Technology
| Email alert
Add to watchlist
VRTX | $397.48 0.24% 0.23% 1.4M
|
Health Technology
| Email alert
Add to watchlist
RARE | $42.87 -8.79% -9.63% 1.7M
|
Health Technology
| Email alert
Add to watchlist
SLDB | $9.99 -3.66% -3.8% 150K
|
Health Technology
| Email alert
Add to watchlist
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
| Email alert
Add to watchlist
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
BLUE | $1.035 -5.91% -6.28% 7.6M
|
Health Technology
| Email alert
Add to watchlist
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
| Email alert
Add to watchlist
DTIL | $13.02 -7.79% -8.45% 110K
|
Health Technology
| Email alert
Add to watchlist
global therapy market
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
Published: 2023-12-28 (Crawled : 00:00) - prnewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: -1.32%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.08%
H: 0.81%
C: -0.19%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.52%
H: 0.72%
C: -0.34%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 0.35%
H: 1.07%
C: -0.27%
candidate tumors collaboration trial advanced china therapy
Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
Published: 2023-10-26 (Crawled : 13:00) - biospace.com/
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: -1.68%
H: 0.0%
C: 0.0%
DTIL | $13.02 -7.79% -8.45% 110K
|
Health Technology
|
| O: 1.43%
H: 3.28%
C: 0.17%
congress cell arcus preclinical therapy
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
Published: 2023-10-02 (Crawled : 14:00) - biospace.com/
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: -1.77%
H: 0.0%
C: 0.0%
NKTR | $1.56 -6.59% -7.05% 2.8M
|
Health Technology
|
| O: -2.01%
H: 4.52%
C: -2.35%
t-cell congress therapeutics therapy
Insights Into the Global Alzheimer's Disease Market, 2023-2032 - Eli Lilly's Donanemab Poised as Front-Runner for 2024 Market Debut, Set to Rival Biogen and Eisai's LEQEMBI in Emerging Therapy Arena
Published: 2023-08-18 (Crawled : 19:00) - prnewswire.com
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
leqembi disease global alzheimer's set therapy market
Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy
Published: 2023-08-04 (Crawled : 12:00) - biospace.com/
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: 0.0%
retevmo plus therapy
Testosterone Replacement Therapy Market to Reach $2.22 Billion by 2027, Driven by Rising Testosterone Deficiency Cases
Published: 2023-07-25 (Crawled : 00:00) - prnewswire.com
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: -0.34%
H: 0.69%
C: -0.05%
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
|
| O: -0.62%
H: 0.0%
C: 0.0%
reach therapy market
Major Players Abbott, Pfizer, and Novartis Drive Growth in Global Hormone Therapy Market to 2032
Published: 2023-07-21 (Crawled : 23:00) - prnewswire.com
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
| Email alert
Add to watchlist
ABT | $108.89 -0.2% 0.04% 4.6M
|
Health Technology
| Email alert
Add to watchlist
PRGO A | $30.13 -0.63% 0.0% 1.7M
|
Health Technology
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | $92.9 -2.18% 880
|
Health Technology
| Email alert
Add to watchlist
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
| Email alert
Add to watchlist
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
| Email alert
Add to watchlist
global novartis therapy growth market hormone
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study
Published: 2023-07-20 (Crawled : 00:00) - globenewswire.com
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.65%
H: 0.49%
C: 0.07%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.35%
H: 2.21%
C: 1.9%
HCM | $17.64 -1.34% -1.36% 63K
|
Health Technology
|
| O: -0.33%
H: 2.55%
C: 1.4%
treatment designation china therapy study
RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors
Published: 2023-07-10 (Crawled : 03:00) - prnewswire.com
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.19%
H: 0.38%
C: 0.04%
rc88 tumors trials potential therapy
Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China
Published: 2023-06-26 (Crawled : 00:00) - prnewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 1.4%
H: 0.0%
C: -2.69%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.4%
H: 0.0%
C: 0.0%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 0.06%
H: 0.91%
C: 0.72%
tyvyt tumors collaboration trial china therapy
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST
Published: 2023-06-02 (Crawled : 00:20) - prnewswire.com
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
| Email alert
Add to watchlist
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | $92.9 -2.18% 880
|
Health Technology
| Email alert
Add to watchlist
treatment designation therapy
Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX®)for KRASG12C-mutated NSCLC in China
Published: 2023-06-02 (Crawled : 00:00) - prnewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -0.56%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.79%
H: 1.08%
C: 0.54%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: -0.02%
H: 1.79%
C: 1.69%
ibi351 erbitux merck germany collaboration trial china therapy
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.